Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City

Eravacycline demonstrated in vitro activity against a contemporary collection of more than 4,000 Gram-negative pathogens from New York City hospitals, with MIC50/MIC90 values, respectively, for Escherichia coli of 0.12/0.5 mu g/ml, Klebsiella pneumoniae of 0.25/1 mu g/ml, Enterobacter aerogenes of 0.25/1 mu g/ml, Enterobacter cloacae 0.5/1 mu g/ml, and Acinetobacter baumannii of 0.5/1 mu g/ml. Activity was retained against multidrug-resistant isolates, including those expressing KPC and OXA carbapenemases. For A. baumannii, eravacycline MICs correlated with increased expression of the adeB gene.